医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Teijin Acquires Exclusive Sales Rights in Asia to BARLEYmax®

2019年06月24日 PM12:00
このエントリーをはてなブックマークに追加


 

TOKYO

Teijin Limited announced today that it has reached an agreement with The Healthy Grain Pty. Limited, an Australian venture company, to acquire the exclusive sales rights in Asia to BARLEYmax® non-genetically modified barley rich in resistant starch and water-soluble dietary fiber, such as β-glucan and fructan. BARLEYmax® was developed by Australia’s national science agency, the Commonwealth Scientific and Industrial Research Organisation.

Teijin, since entering into an exclusive agreement with Healthy Grain to jointly develop BARLEYmax® in Japan in 2015, has expanded domestic sales, conducted clinical trials, developed products by leveraging the special characteristics of various ingredients, and implemented marketing to improve recognition. Teijin has now acquired the exclusive sales rights in Asia and started sales where market expansion is expected, based on its judgment that further global business expansion is essential.

The agreement grants Teijin exclusive marketing rights in Korea, China, Taiwan, Thailand, Indonesia and Singapore, markets suitable for BARLEYmax® due to their local customs of eating rice as well as increasing consumption of functional cereals and rising health consciousness. Teijin initially will focus on these markets, targeting the prompt launch of products in cooperation with local companies and exporting of processed foods from Japan.

Teijin is rapidly expanding its global healthcare business to enhance the quality of life of worldwide by helping people to enjoy fulfilling lives from birth to their final days.

About the Teijin Group

Teijin (TOKYO:3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has over 170 companies and around 20,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY888.6 billion (USD 8.1 billion) and total assets of JPY 1020.7 billion (USD 9.3 billion) in the fiscal year ending March 31, 2019.
Please visit www.teijin.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190623005002/en/

CONTACT

Corporate Communications
Teijin Limited
+81 3 3506 4055
pr@teijin.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 拓臻生物公布其非酒精性脂肪性肝炎(NASH)候选药物-具有肝脏选择性的法尼醇X受体(FXR)激动剂TERN-101-临床Ⅰ期试验安全性和药效学研究结果
  • Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
  • AVITA Medical Half-Year Financial Report for Fiscal 2020
  • 西联汇款启动抗击新型冠状病毒的全球援助项目
  • Jinsan Beverage of Korea Introduces Its 5 Healthy Smoothies for Spring